Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately
The FDA has categorized this as a Class I recall. If patients update their phone or watch apps as needed, they can continue to use these devices like normal.
Why all heart patients should be vaccinated against the flu, COVID-19, RSV
The American College of Cardiology has shared new recommendations highlighting the protective benefits of a variety of vaccines. The new guidance also examines how to speak with patients who are hesitant to be vaccinated.
First study of its kind to focus on new therapy for hypoplastic left heart syndrome
The new trial represents a potential breakthrough in the treatment of one of the most devastating congenital heart defects.
Real-world data link semaglutide, tirzepatide to improved heart failure outcomes
GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.
Beta blockers ‘have no effect’ on heart attack patients
One researcher described the study's findings as "one of the most significant advances in heart attack treatment in decades.”

The Dexcom G7 Continuous Glucose Monitoring System

Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately

The FDA has categorized this as a Class I recall. If patients update their phone or watch apps as needed, they can continue to use these devices like normal.

COVID-19 vaccine vaccination myocarditis heart damage inflammation RSNA imaging radiology cardiology

Why all heart patients should be vaccinated against the flu, COVID-19, RSV

The American College of Cardiology has shared new recommendations highlighting the protective benefits of a variety of vaccines. The new guidance also examines how to speak with patients who are hesitant to be vaccinated.

Joshua M. Hare, MD, FACC, FAHA, a professor of medicine, molecular and cellular pharmacology, and biomedical engineering, director of regenerative medicine, and director of the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami, and co-founder and chief science officer for the stem cell start-up Longeveron, explains the FDA trial for laromestrocel (Lomecel-B) to treat hypoplastic left heart syndrome (HLHS).

First study of its kind to focus on new therapy for hypoplastic left heart syndrome

The new trial represents a potential breakthrough in the treatment of one of the most devastating congenital heart defects.

Real-world data link semaglutide, tirzepatide to improved heart failure outcomes

GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.

Beta blockers ‘have no effect’ on heart attack patients

One researcher described the study's findings as "one of the most significant advances in heart attack treatment in decades.”

An attendee at AHA 2024 looking at educational displays on Lp(a) in the Novartis booth. Photo By Dave Fornell

Health systems use AI to target patients who may have elevated Lp(a) levels

"We can start helping people right now, and it would be meaningful if we can raise more awareness to reduce the burden of CVD," explained Katherine Wilemon, founder and CEO of the Family Heart Foundation.

Oral GLP-1 drug linked to weight loss in patients with and without diabetes—is FDA approval next?

Eli Lilly and Company is back with even more positive data on orforglipron, its oral GLP-1 receptor agonist. The company says it is "moving with urgency" toward gaining key regulatory approvals and getting the drug in the hands of patients.

FDA clears new trial of first-in-class treatment for pulmonary arterial hypertension

The new drug, VTB-10, previously received the FDA's orphan drug designation in 2024.